Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer and CureVac collaborate on Covid-19 vaccine candidate
As per terms of the deal, Bayer will extend its support for further development, supply and crucial territory operations of CureVac´s Covid-19 vaccine candidate. By the end of
As per terms of the deal, Bayer will extend its support for further development, supply and crucial territory operations of CureVac´s Covid-19 vaccine candidate. By the end of
The FDA’s Fast Track designation is designed to help progress development and speed up the review of novel therapies for serious conditions for which there is an unmet
The conditional marketing authorisation is based on the recommendation of the European Medicines Agency (EMA) for use of the Covid-19 Vaccine Moderna for active immunisation to prevent Covid-19
Fujifilm stated that it is establishing the new manufacturing site to boost the growth of its biopharmaceutical contract development and manufacturing business (CDMO). The company’s subsidiary Fujifilm Diosynth
Under the deal, LakePharma will produce Akston’s adjuvanted Covid-19 vaccine candidate (AKS-452), which is slated to start phase 1/2 clinical testing later this month. LakePharma president and CEO
CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. CUREfilm Blue utilizes the Company’s patented and proprietary fast-dissolving drug
The breakthrough therapy designation allows the combination therapy as a first-line treatment for people with metastatic NSCLC whose tumours have high PD-L1 expression with no EGFR or ALK
“This is an important milestone for ARX788 that underscores the strong unmet medical need to develop new and effective treatment options for breast cancer patients whose tumors progressed
Arvelle Therapeutics is involved in the development of advanced solutions to treat patients suffering from central nervous system (CNS) disorders. The company is currently engaged in the development
Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase designed to be used as subcutaneous (SC) injection. Phesgo integrates the same monoclonal antibodies as